$-0.21 EPS Expected for Compugen Ltd. (CGEN) on May, 8

April 16, 2018 - By Andrea Pope

Compugen Ltd. (NASDAQ:CGEN) Corporate Logo

On May, 8. Investors expect Compugen Ltd. (NASDAQ:CGEN) to report its quarterly earnings, Faxor reports. Analysts have expectation on stock’s EPS of $-0.21. That’s down 23.53 % from last year’s $-0.17 EPS. Analysts at Wall Street see Compugen Ltd.’s 16.67 % negative EPS growth compared to $-0.18 EPS for last quarter. CGEN reached $4.3 on during the last trading session after $0.2 change.Currently Compugen Ltd. is downtrending after 8.14% change in last April 17, 2017. CGEN has also 154,185 shares volume. The stock underperformed the S&P 500 by 19.69%.

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe.The firm is valued at $222.71 million. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations.Last it reported negative earnings. The Company’s antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.